Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

PURPOSE: Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, contemporary experience with ipilimumab treatment outside of clinical trials to determine the frequency of use of systemic corticosteroi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Horvat, Troy Z., Adel, Nelly G., Dang, Thu-Oanh, Momtaz, Parisa, Postow, Michael A., Callahan, Margaret K., Carvajal, Richard D., Dickson, Mark A., D'Angelo, Sandra P., Woo, Kaitlin M., Panageas, Katherine S., Wolchok, Jedd D., Chapman, Paul B.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087335/
https://ncbi.nlm.nih.gov/pubmed/26282644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.60.8448
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados